Pain management, fluid therapy and thromboprophylaxis after pancreatoduodenectomy: a worldwide survey among surgeons

Jesse V. Groen1, Rutger B. Henrar1, Randa G. Hanna Sawires1, Essa AlEassa2, Chris H. Martini3, Bert A. Bonsing1, Alexander L. Vahmeijer1, Marc G. Besselink4, Nicolo Pecorelli5, Thilo Hackert6, Takeaki Ishizawa7, Timothy Miller8, Timothy H. Mungroop9, Jaswinder Samra9, Alain Sauvanet10, Mustapha Adham11, Nicolas Demartines12, Chris Christophi13, Gareth Morris-Stiff9,12 & J. Sven D. Mieog1*

1Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands, 2Hepato-Biliary Pancreatic Surgery, Digestive Diseases and Surgery, Cleveland Clinic Institute, Cleveland, USA, 3Department of Anaesthesiology, Leiden University Medical Center, Leiden, 4Department of Surgery, Amsterdam UMC, Amsterdam, the Netherlands, 5Division of Pancreatic Surgery, Pancreas Translational & Clinical Research Center, San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, 6Department of Surgery, University of Heidelberg, Heidelberg, Germany, 7Hepato-Biliary-Pancreatic Surgery Division, University of Tokyo, Tokyo, Japan, 8Department of Anaesthesiology, Duke University School of Medicine, Durham, USA, 9Upper GI Surgical Unit, Department of Gastrointestinal Surgery, Royal North Shore Hospital, Sydney, Australia, 10Department of Digestive Surgery and Transplantation, Beaujon Hospital, Clichy, 11Department of Digestive Surgery, Hopital Edouard Herriot, Lyon, France, 12Department of Visceral Surgery, University Hospital Lausanne (CHUV), University of Lausanne, Lausanne, Switzerland, and 13Department of Surgery, The University of Melbourne, Austin Health, Melbourne, Victoria, Australia

Abstract

Background: The aim of this survey was to assess practices regarding pain management, fluid therapy and thromboprophylaxis in patients undergoing pancreatoduodenectomy on a global basis.

Methods: This survey study among surgeons from eight (inter)national scientific societies was performed according to the CHERRIES guideline.

Results: Overall, 236 surgeons completed the survey. ERAS protocols are used by 61% of surgeons and respectively 82%, 93%, 57% believed there is a relationship between pain management, fluid therapy, and thromboprophylaxis and clinical outcomes. Epidural analgesia (50%) was most popular followed by intravenous morphine (24%). A restrictive fluid therapy was used by 58% of surgeons. Chemical thromboprophylaxis was used by 88% of surgeons. Variations were observed between continents, most interesting being the choice for analgesic technique (transversus abdominis plane block was popular in North America), restrictive fluid therapy (little use in Asia and Oceania) and duration of chemical thromboprophylaxis (large variation).

Conclusion: The results of this international survey showed that only 61% of surgeons practice ERAS protocols. Although the majority of surgeons presume a relationship between pain management, fluid therapy and thromboprophylaxis and clinical outcomes, variations in practices were observed. Additional studies are needed to further optimize, standardize and implement ERAS protocols after pancreatic surgery.

Received 8 April 2021; accepted 6 September 2021

Correspondence

J.S.D. Mieog, Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2300, RC Leiden, the Netherlands. E-mail: J.S.D.Mieog@lumc.nl (J.S.D. Mieog)

Correspondence

J.V. Groen., Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2300, RC Leiden, the Netherlands E-mail: J.V.Groen@lumc.nl (J.V. Groen)

* These authors contributed equally and share senior authorship.
Introduction

There is increasing interest in Enhanced Recovery After Surgery (ERAS) protocols as a means of improving clinical outcomes, although to date there is limited data on pancreatoduodenectomy (PD). Pain management, fluid therapy and thromboprophylaxis are among key elements in all ERAS protocols and are believed to be equally important following PD. Recent studies have shown an association between low compliance to ERAS protocols and decreased clinical outcomes such as more overall, respiratory, infectious, and major complications (Clavien-Dindo ≥ III), longer length of hospital stay and more readmissions following PD.1–3

Although epidural analgesia is recommended over intravenous morphine in the recent ERAS Society guideline for PD(1), the optimal pain management remains controversial, and the reported use of epidural analgesia varies from 11 to 85%.6 There are only a few well-conducted randomized controlled pain management trials reporting on patients undergoing PD7–9 and to date the role of transversus abdominis plane blocks has not been assessed for these patients.

Avoidance of fluid overload and a goal-directed fluid therapy algorithm using intra- and postoperative non-invasive monitoring are recommended in the ERAS Society guidelines for PD.1 Recent randomized trials on liberal or restrictive fluid therapy have brought conflicting evidence and have not led to a consensus.10–12 A recent meta-analysis revealed an association between restrictive fluid therapy and lower mortality, although no association with morbidity was observed. It was concluded that more research is needed, ideally by collaboration of surgeons, anaesthesiologists and critical care physicians.13

The ERAS Society guidelines for PD recommends mechanical and chemical thromboprophylaxis (low molecular weight or unfractionated heparin) until hospital discharge and extended thromboprophylaxis (four weeks) in patients with cancer.1 Although many (inter)national thromboprophylaxis guidelines are available, there is still debate about the choice and duration of the appropriate thromboprophylaxis.14 Despite all guidelines recommend extended thromboprophylaxis in patients with cancer, there is no specific definition.15

The aim of this study was to obtain a global assessment of current perioperative practices regarding pain management, fluid therapy and thromboprophylaxis in patients undergoing PD among surgeons.

Methods

Study design and participants

This survey study was performed and reported according to the Checklist for Reporting Results of Internet E-Surveys (CHERRIES).16 Institutional Review Board approval was not requested since no patients were involved and informed consent was implied when participants completed the survey.

An online survey (LimeSurvey: https://www.limesurvey.org) was designed in collaboration within an international research team. The survey was tested for usability and technical functionality. An invitation e-mail for the closed-survey (i.e. only accessible through invitation) was sent out from November 2019 through July 2020 to members of six international societies (International Hepato-Pancreato and Biliary Association (HPBA), Americas-HPBA, Asian-Pacific-HPBA, Australia-New Zealand-HPBA, Enhanced Recovery After Surgery Society and American Society for Enhanced Recovery) and two national societies (Association de chirurgie hépato-bilio-pancréatique et transplantation, Society of American Gastrointestinal and Endoscopic Surgeons). The link to the survey also appeared on several social media channels.

In the invitation e-mail, participants were informed about the topic, research team and aim of the survey, the duration (~5 min) and the fact that all answers were being collected anonymously. Participants received up to three reminders. The survey was closed end of July 2020. The total number of invited participants and response rates was not calculated, since there is overlap between memberships of the international and national associations. IP addresses or cookies were used to prevent multiple responses by the same individual and were deleted after the survey was closed.

Survey

The content of the survey is provided in the Supplementary Material (File 1). The first part of the survey consisted of questions regarding characteristics of the participants, for example: scope of practice, experience, and annual volume. The second part of the survey was focused on pain management: analgesic technique, standardized protocols, availability of an acute pain service, most effective analgesic technique, and the presumed relationship between analgesic technique and clinical outcome. The third part of the survey covered issues concerning fluid therapy: standardized protocols, type of fluid therapy, means of monitoring, and presumed relationship between fluid therapy and clinical outcome. The fourth and final part of the survey examined thromboprophylaxis practices: the use of mechanical and chemical thromboprophylaxis, duration of thromboprophylaxis, indications for thromboprophylaxis, and presumed relationship between thromboprophylaxis and clinical outcome.

Survey questions included multiple-choice and open questions and were not randomized or altered. Adaptive questioning was used based on the answers in the survey. The survey consisted of 8 pages and a total of 41 questions. A completeness check was performed before submission of the survey and participants were given the chance to review and change their answers. No time limit was set for filling in the survey. Responders were given the option to include their information (e-mail address) separately to receive the study results. No other incentives were offered.
Statistical analyses
No weighting of items or propensity score matching was used to adjust for a potential non-representative sample. Participants who did not complete the first part of the survey (characteristics) were excluded. Continuous variables were presented as median with interquartile range (IQR). Categorical variables were presented as numbers (percentages) and compared by means of Chi-square or Fisher’s Exact tests. Participants were analysed in total and compared by continent. IBM SPSS Statistics for Windows, version 23.0 (IBM Corp., Armonk, N.Y., USA) was used for statistical analysis.

Results
Participants
In total, 272 surgeons responded to the survey during its open window between November 2019 and July 2020 (Table 1). Thirty-six responses were excluded since they did not complete page 2 (first part of the survey on characteristics). Most participants were from Europe (42%), North America (21%) and Asia (19%). The median age of participants was 45 years old (IQR 37 – 54), the majority were male (86%), were employed at an academic hospital (79%) and the scope of practice was hepatopancreatobiliary surgery (71%). In 20% there were a dedicated pancreatic surgeon and anaesthesiologist, in 60% there was a dedicated pancreatic surgeon and in 21% there was no dedicated team. ERAS protocols after pancreatic surgery were practiced in 61% of the participants’ institutes (Fig. 1). The highest rates of practising ERAS protocols were reported in North America (73%) and Asia (72%) (Fig. 1). ERAS protocols were practiced by 62% of surgeons employed at an academic and 54% of surgeons employed at a non-academic hospital (P = 0.425).

Pain management
Overall, the most frequently used analgesic technique for an open PD was epidural analgesia (50%), followed by intravenous morphine (24%), spinal analgesia (10%), transversus abdominis plane block (9%), and continuous wound infiltration (8%) (Fig. 2).

In 36% of responses, the surgical staff was responsible for postoperative pain management, in 34% the anaesthesiology staff, and in 26% a dedicated acute pain service team (Table 2). Initial analgesia was stopped before or on postoperative day 3 in 75% of patients and in 25% on postoperative day 4 or later. After discontinuation of the initial analgesic technique, a standardized protocol was used by 65% of participants. In case of minimally invasive (laparoscopic or robot assisted) PD, 51% of participants used a different analgesia technique (Fig. 3). An association between the choice of perioperative analgesia technique and clinical outcome after PD was assumed by 82% of participants (Fig. 1).

Epidural analgesia and intravenous morphine were the most frequently used analgesic technique in all continents, except for North America, where the transversus abdominis plane block was almost equally popular (Fig. 2). The responsibility for postoperative pain management was more clearly distributed in North America, 61% of participants reported that the surgical

| Question                                                                 | Surgeons | %   |
|--------------------------------------------------------------------------|----------|-----|
| What is your scope of practice?                                          |          |     |
| HPB                                                                      | 168      | 71.2|
| Surgical oncology                                                        | 28       | 11.9|
| Transplant surgery                                                       | 3        | 1.3 |
| General surgery                                                          | 29       | 12.3|
| Other                                                                    | 8        | 3.4 |
| What is your sex?                                                        |          |     |
| Male                                                                    | 203      | 86.4|
| Female                                                                  | 32       | 13.6|
| Missing                                                                 | 1        |     |
| What is your age in years?                                               |          |     |
| Median (IQR)                                                            | 45       | 37–54|
| Missing                                                                 | 2        |     |
| How many years of work experience do you have after your residency?      |          |     |
| Median (IQR)                                                            | 12       | 5–22|
| In which continent do you work?                                          |          |     |
| North America                                                           | 49       | 20.8|
| South America                                                           | 15       | 6.4 |
| Europe                                                                  | 100      | 42.4|
| Africa                                                                   | 4        | 1.7 |
| Asia                                                                    | 45       | 19.1|
| Oceania                                                                 | 23       | 9.7 |
| Are you employed at an academic hospital?                                |          |     |
| Yes                                                                     | 161      | 78.5|
| No                                                                      | 44       | 21.5|
| Missing                                                                 | 31       |     |
| How many PDs does your institution perform annually?                     |          |     |
| Median (IQR)                                                            | 35       | 20–60|
| How many PDs do you perform annually?                                   |          |     |
| Median (IQR)                                                            | 15       | 7–29|
| Missing                                                                 | 40       |     |
| Is there a dedicated team for pancreatic surgery?                       |          |     |
| Yes, both a pancreatic surgeon and anaesthesiologists                  | 40       | 19.5|
| Yes, a pancreatic surgeon                                               | 122      | 59.5|
| No, there is no dedicated team                                          | 42       | 20.5|
| Other                                                                   | 1        | 0.5 |
| Missing                                                                 | 31       |     |

Abbreviations: HPB: hepatopancreatobiliary; IQR: interquartile range; PD: pancreatoduodenectomy

Please cite this article as: Groen JV et al., Pain management, fluid therapy and thromboprophylaxis after pancreatoduodenectomy: a worldwide survey among surgeons, HPB, https://doi.org/10.1016/j.hpb.2021.09.006
Figure 1 Practice of ERAS protocols following pancreatic surgery and the presumed relationship between perioperative analgesic technique, fluid therapy, thromboprophylaxis, and clinical outcome after PD. P-value for Chi-square or Fisher’s Exact tests between continents.

Figure 2 Most popular perioperative analgesic technique in patients undergoing PD. *Question: Organize the analgesia techniques by descending frequency of use following open pancreatoduodenectomy.
Table 2 Perioperative pain management and fluid therapy in patients undergoing PD

Table 2 (continued)

| Question | Surgeons |
|----------|---------|
| **Perioperative fluid therapy** | |
| Does your institution have a standardized protocol for fluid management during open PD? | |
| Yes | 96 | 53.6 |
| No | 83 | 46.4 |
| Missing | 57 |
| Does the protocol at your institution describe the use of restrictive fluid therapy (near zero fluid balance) during and following open PD? | |
| Yes | 103 | 57.5 |
| No | 76 | 42.5 |
| Missing | 57 |
| Do you replace fluid volume according to output of drainage tubes (enteral tube, abdominal drains, biliary/pancreatic drains) following PD? | |
| Yes | 102 | 57.3 |
| No | 76 | 42.7 |
| Missing | 58 |
| What is the planned destination for patients during the first night following open pancreatoduodenectomy? | |
| Monitored environment (intensive or medium care unit, post anaesthesia care unit) | 137 | 76.5 |
| Monitored on ward | 30 | 16.8 |
| Unmonitored on ward | 12 | 6.7 |
| Missing | 57 |

**Abbreviations:** POD: postoperative day; PD: pancreatoduodenectomy.

staff was responsible, and in Oceania, 79% reported that the dedicated acute pain service was responsible (Table S1). The assumed relationship between choice of analgesic technique and clinical outcome varied between the continents; with 88% assuming a relationship in Asia and North America and 63% in Oceania (Figure S1).

**Fluid therapy**

A standardized protocol for fluid management was used by 54% of participants for an open PD and 58% reported the use of restrictive fluid therapy in the protocol (Table 2). In case of a minimally invasive procedure 30% of participants used a different protocol (Fig. 3). The first night after surgery 94% of participants reported that patients were admitted to a monitored environment. An association between the choice of perioperative
fluid management and clinical outcome after PD was assumed by 93% of participants (Fig. 1).

In contrast to the other continents, a minority of participants in Asia (44%) and Oceania (39%) reported the use of restrictive fluid therapy (Table S1). Little variation in the assumed relationship between choice of fluid management and clinical outcome was reported between continents (89–100%) (Fig. 1).

Thromboprophylaxis

The use of mechanical thromboprophylaxis was reported by 90% of participants (Table 3). The most used mechanical prophylaxis following open PD were early mobilization (77%), TED stockings (66%) and calf compression (61%). The use of chemical thromboprophylaxis was reported by 88% of participants following open PD. Most participants stopped the chemical prophylaxis on discharge (27%) or four weeks after surgery (52%) (Fig. 4).

Different thromboprophylaxis protocols were used in 23% for a benign indication and in 7% for a minimally invasive PD (Table 3, Fig. 3). Different thromboprophylaxis protocols were also used in 40% in case of an arterial resection and 23% in case of a venous resection (Fig. 4). Most participants added a platelet inhibitor for an arterial (68%) or a venous (47%) resection. An association between the choice of thromboprophylaxis and clinical outcome after PD was assumed by 57% of participants (Fig. 1).

In comparison to other continents, participants from Asia reported limited use of chemical thromboprophylaxis (48%) in their protocols (Table S1). The majority in Asia preferred to stop chemical thromboprophylaxis when the patient was mobile (50%), in North America at discharge (48%) and in Europe and Oceania at four weeks postoperatively (76% and 56%) (Fig. 4).

For an arterial or venous resection, in Oceania a different protocol was used in 11% and 0%, in contrast to 48% and 40% in North America and 55% and 23% in Asia (Table S1). The assumed relationship between choice of prophylaxis and clinical outcome varied between the continents; with 80% in North America assuming a relationship and only 33% in Oceania (Fig. 1).

Discussion

This international survey of 236 surgeons gives insight into the current global perioperative practices regarding pain management, fluid therapy and thromboprophylaxis in patients undergoing PD. This survey demonstrates tremendous variation in perioperative practice by pancreatic surgeons around the world. Furthermore, there is limited compliance to the current ERAS Society guideline for PD(1) regarding pain management, fluid therapy and thromboprophylaxis and only 61% of surgeons practice ERAS protocols. Most surgeons assume a relationship between pain management, fluid therapy and thromboprophylaxis and clinical outcome following PD, respectively 82%, 93% and 57%. The preferred method for analgesia was epidural

---

Table 3 Thromboprophylaxis in patients undergoing PD

| Question | Surgeons |
| --- | --- |
| | N | % |
| Does the protocol at your institution describe the use of mechanical thromboprophylaxis? | | |
| Yes | 155 | 90.1 |
| No | 17 | 9.9 |
| Missing | 64 | |
| Which methods of mechanical thromboprophylaxis are used following open PD? | | |
| TED stockings | 102 | 65.8 |
| Calf compressors | 95 | 61.3 |
| Foot-pump | 27 | 17.4 |
| Early mobilization | 120 | 77.4 |
| Other | 1 | 0.6 |
| Does the protocol describe the use chemical thromboprophylaxis following open PD? | | |
| Yes | 151 | 87.8 |
| No | 21 | 12.2 |
| Missing | 64 | |
| Would you use a different protocol of thromboprophylaxis if this was a patient with a benign indication for PD? | | |
| Yes | 38 | 22.5 |
| No | 131 | 77.5 |
| Missing | 67 | |

Abbreviations: TED: Thrombo-embolic deterrent; LMWH: low-molecular weight heparin; PD: pancreatoduodenectomy.

For an arterial or venous resection, in Oceania a different protocol was used in 11% and 0%, in contrast to 48% and 40% in North America and 55% and 23% in Asia (Table S1). The assumed relationship between choice of prophylaxis and clinical outcome varied between the continents; with 80% in North America assuming a relationship and only 33% in Oceania (Fig. 1).
analgesia (50%), followed by intravenous morphine (25%). Restrictive fluid therapy is practiced by 58% of surgeons. Mechanical and chemical thromboprophylaxis are frequently used after PD (90% and 88%), however the duration of chemical prophylaxis varies. In case of minimally invasive surgery most surgeons only changed the analgesia technique (51%), but did not amend fluid therapy (30%) or thromboprophylaxis (7%). Variations between continents exist, mainly related to the choice of analgesia technique, use of restrictive fluid therapy, and duration of chemical thromboprophylaxis.

Postoperative pain management is one of the most important pillars of ERAS strategies as adequate pain management leads to shorter hospital stay and less postoperative complications. Epidural analgesia is the most used analgesic technique, in line with the current ERAS Society guideline for PD which strongly recommends epidural analgesia and a multimodal opioid sparing strategy.\(^1\) A previous meta-analysis of non-randomized studies showed a marginal difference with a questionable clinical relevance in mean pain scores between epidural analgesia and intravenous morphine, yet did confirm a reduction in complications, length of stay and mortality in patients receiving epidural analgesia.\(^5\) However, a recent randomized study observed conflicting results with similar gastrointestinal morbidity for both analgesic techniques.\(^9\) The ERAS Society guideline for PD also states the use of continuous wound infiltration as a reasonable alternative to epidural analgesia.\(^1\) In spite of this recommendation, the use of continuous wound infiltration was rarely reported in the survey. Interestingly, in North America the transversus abdominis plane block was highly ranked as the most commonly used technique for analgesia, although this preference was not reported on other continents. This is probably due to personal preferences and experience, since no research has been done on the effectiveness of this analgesic technique in PD. Although it has been shown to be beneficial following other upper gastrointestinal resections including hepatectomy and gastrectomy.\(^18,19\) In the survey, 66% of surgeons preferred patient controlled analgesia over continuous infusion. Despite evidence of improved effectiveness and higher patient satisfaction within other fields of surgery\(^20\), few studies have investigated this in pancreatic surgery.\(^6\) More
research is needed to determine the optimal analgesic technique for open PD and separately for minimally invasive procedures. Half of the surgeons reported the use of a different analgesic technique in minimally invasive PD, without studies being available which investigated this.

The importance of fluid therapy is affirmed by the high assumed association with clinical outcome (93%). However, the optimal protocol for fluid management is still under debate, due to the use of varying definitions (liberal, restrictive, zero-balance fluid therapy) and low compliance rates. This is confirmed in the survey by the large variation in clinical practices. The current ERAS Society guideline for PD strongly recommends avoiding fluid overload to improve outcomes. Despite this recommendation, only 58% of surgeons report the use of restrictive fluid therapy in their institutional protocol. Interestingly, Asia and Oceania reported relatively little use of restrictive fluid therapy and yet do largely assume an association with clinical outcome. A randomized trial in the context of an ERAS protocol found that intraoperative goal directed fluid therapy reduced administration of (intraoperative) fluids, shortened the length of hospital stay and reduced postoperative complications in patients undergoing PD. Additional research is needed to confirm these results and optimize the goal directed fluid therapy protocols, also for minimally invasive procedures.

Thromboprophylaxis protocols are considered one of the highest levels of evidence available in ERAS Society guideline for PD. The recommendation to use extended chemical prophylaxis of four weeks for cancer is only practiced by 52% of surgeons. Especially in Asia and North America, prophylaxis is often discontinued when a patient is mobile or discharged. This poor adherence to the ERAS Society guideline for PD might be explained by differences in health care systems or cultural objections to self-injection of chemical thromboprophylaxis. Few surgeons used a different protocol for a benign indication, possibly exposing these patients to an unnecessary higher risk of four weeks of prophylaxis. In a previous study, we investigated three different thromboprophylaxis regimens and concluded that a high dose of nadroparin (5700IU once daily) for six weeks is associated with an increased risk of post-pancreatectomy haemorrhage. The benefits of (extended) thromboprophylaxis should be carefully reconsidered in case of risk factors for post-pancreatectomy haemorrhage such as postoperative pancreatic fistula. The use of mechanical prophylaxis was widespread in our survey with a weak recommendation in the guideline as an additional measure. However, the compliance to early mobilization has been shown to be difficult, possibly due to the frequent use of epidural analgesia. Standard use of physiotherapists could help stimulate a higher compliance rate. It is questionable if there is enough support to further investigate the optimal thromboprophylaxis protocol due to a relatively low assumed association with clinical outcome (53%). Patients with vascular resections are at high risk of thrombosis. Our survey showed that 40% and 23% used a different protocol for arterial and venous resections and there were large variations in type, dose and duration of the thromboprophylaxis protocols. This could create possibilities for optimizing the thromboprophylaxis in these high-risk patients.

This survey does have some limitations. Firstly, the sample is rather small and heterogeneous (for example the distribution among the different continents). Furthermore, the exact number of invited participants and the response rate remain unknown. Secondly, the relatively high representation of academic surgeons that could be explained by potential selection bias due to the participation of several (inter)national scientific societies. However, since PD is increasingly being centralized to high-volume centres, the sample could equally be considered representative. Lastly, responses are preferences and perceptions of individuals (response bias) were not confirmed by patient-data.

Overall, the observed variations in perioperative practice have to be considered during interpretation and extrapolation of study results to other hospitals or regions. This study also highlights the issue of surgeons not practicing evidence-based medicine. The exact reasons for the choice of specific perioperative practices were not surveyed in this study. Another survey study among surgeons showed that the most common reasons for not implementing recommended practices are: scepticism regarding the validity of the applied methodology of the available evidence, low clinical relevance and organizational or financial considerations. Clinically relevant and well-designed randomized trials with adequate methodology and external validity and global dissemination of the results (besides conventional methods, visual abstracts and videos have a high potential) are needed to increase the compliance to recommended practices. This will create more uniformity of protocols over the globe and further optimize the perioperative care after PD.

In conclusion, this international survey showed that there is a limited compliance to the current ERAS Society guidelines for PD and only 61% of surgeons practice to ERAS protocols. Although the majority of surgeons presume a relationship between pain management, fluid therapy, thromboprophylaxis, and clinical outcomes, large variations in practices were observed. Additional studies are needed to further optimize, standardize, and implement ERAS protocols after pancreatic surgery into daily practice.

Ethics approval and consent to participate
This study was performed in accordance with the Declaration of Helsinki. Institutional Review Board approval was not requested since no patients were involved. Informed consent was implied when participants completed the survey.

Consent for publication
Not applicable.
Data availability
The dataset used during this study is available upon reasonable request from the corresponding author.

Previous communication
None.

Author justification
Concept and design of the manuscript: All authors.
Data acquisition, analysis and interpretation: JVG, RBH, GMS, JSDM.
Drafting of the manuscript: JVG, RBH.
Critical revision of the manuscript: All authors.

Acknowledgments
The authors would like to thank all participating surgeons who completed the survey. The authors would also like to thank A. Hamming (Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands), J. Vuyl and A. Dahan (Department of Anaesthesiology, Leiden University Medical Centre, Leiden, The Netherlands) for their help in designing the survey.

Conflict of interest
None declared.

References
1. Melloul E, Lassen K, Roulin D, Grass F, Perinel J, Adham M et al. (2020) Guidelines for perioperative care for pancreateoduodenectomy: enhanced recovery after surgery (ERAS) recommendations 2019. World J Surg 44:2056–2084.
2. Ji HB, Zhu WT, Wei Q, Wang XX, Wang HB, Chen QP. (2018) Impact of enhanced recovery after surgery programs on pancreatic surgery: a meta-analysis. World J Gastroenterol 24:1666–1678.
3. Wang XY, Cai JP, Huang CS, Huang XT, Yin XY. (2020) Impact of enhanced recovery after surgery protocol on pancreaticoduodenectomy: a meta-analysis of non-randomized and randomized controlled trials. HPB (Oxford) 22:1373–1383.
4. Karunakaran M, Barreto SG, Singh MK, Kapoor D, Chaudhary A. (2020) Deviations from a clinical pathway post pancreateoduodenectomy predict 90-day unplanned re-admission. Future Oncol 16:1839–1849.
5. Roulin D, Melloul E, Welg BE, Izbiciki J, Vrochides D, Adham M et al. (2020) Feasibility of an enhanced recovery protocol for elective pancreateoduodenectomy: a multicenter international cohort study. World J Surg 44:2761–2769.
6. Groen JV, Khawar AAJ, Bauer PA, Bonsing BA, Martinhi CH, Mungroop TH et al. (2019) Meta-analysis of epidural analgesia in patients undergoing pancreateoduodenectomy. 3(8):559–571.
7. Hutchins JL, Grandelis AJ, Kaizer AM, Jensen EH. (2018) Thoracic paravertebral block versus thoracic epidural analgesia for post-operative pain control in open pancreatic surgery: a randomized controlled trial. J Clin Anesth 48:41–45.
8. Mungroop TH, Veelo DP, Busch OR, van Dieren S, van Gulik TM, Karsten TM et al. (2016) Continuous wound infiltration versus epidural analgesia after hepatopancreato-biliary surgery (POP-UP): a randomized controlled, open-label, non-inferiority trial. Lancet Gastroenterol Hepatol 1:105–113.
9. Kiotz R, Larmann J, Kloese C, Bruckner T, Benner L, Doerr-Harim C et al. (2020) Gastrointestinal complications after pancreateoduodenectomy with epidural vs patient-controlled intravenous analgesia: a randomized clinical trial. JAMA Surg 155:200794.
10. Fischer M, Matsuo K, Gonen M, Grant F, Dematteo RP, D’Angelica MI et al. (2010) Relationship between intraoperative fluid administration and perioperative outcome after pancreateoduodenectomy: results of a prospective randomized trial of acute normovolemic hemodilution compared with standard intraoperative management. Ann Surg 252:952–958.
11. Lavu H, Sell NM, Carter TI, Winter JM, Maguire DP, Gratch DM et al. (2014) The HYSLAR trial: a prospective randomized controlled trial of the use of a restrictive fluid regimen with 3% hypertonic saline versus lactated Ringers in patients undergoing pancreateoduodenectomy. Ann Surg 260:445–453. discussion 53-5.
12. Myles PS, Bellomo R, Corcoran T, Forbes A, Peyton P, Story D et al. (2018) Restrictive versus liberal fluid therapy for major abdominal surgery. N Engl J Med 378:2263–2274.
13. Garland ML, Mace HS, MacCormick AD, McCluskey SA, Lightfoot NJ. (2019) Restrictive versus liberal fluid regimens in patients undergoing pancreateoduodenectomy: a systematic review and meta-analysis. J Gastrointest Surg 23:1250–1265.
14. Mastoraki A, Mastoraki S, Schizas D, Patras R, Krinos N, Papanikolaou IS et al. (2018) Facing the challenge of venous thromboembolism prevention in patients undergoing major abdominal surgical procedures for gastrointestinal cancer. World J Gastrointest Oncol 10:328–335.
15. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP et al. (2013) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2189–2204.
16. Eysenbach G. (2004) Improving the quality of web surveys: the checklist for reporting results of Internet E-surveys (CHERRIES). J Med Internet Res 6:e34.
17. Kehlet H, Holte K. (2001) Effect of postoperative analgesia on surgical outcome. Br J Anaesth 87:62–72.
18. Huang HM, Chen RX, Zhu LM, Zhao WS, Ye XJ, Luo JW et al. (2020) Combined use of transversus abdominis plane block and laryngeal mask airway during implementing ERAS programs for patients with primary liver cancer: a randomized controlled trial. Sci Rep 10:14892.
19. Liu R, Qin H, Wang M, Li K, Zhao G. (2019) Transversus abdominis plane block with general anesthesia blunts the perioperative stress response in patients undergoing radical gastrectomy. 19(1):205.
20. Momeni M, Crucitti M, De Kock M. (2006) Patient-controlled analgesia with epidural vs patient-controlled intravenous analgesia: a randomized clinical trial. Br J Anaesth 97:62–67.
21. Weinberg L, Ianno D, Churilov L, Chao I, Scurrah N, Rachbuch C et al. (2017) Restrictive intraoperative fluid optimisation algorithm improves outcomes in patients undergoing pancreateoduodenectomy: a prospective multicentre randomized controlled trial. PloS One 12:183313.
22. Hanna-Sawires RG, Groen JV, Klok FA, Tollenaar R, Mesker WE, Swijnenburg RJ et al. (2019) Outcomes following pancreatic surgery using three different thromboprophylaxis regimens. Br J Surg 106:765–773.

23. Chandrasegaram MD, Eslick GD, Lee W, Brooke-Smith ME, Padbury R, Worthley CS et al. (2014) Anticoagulation policy after venous resection with a pancreatectomy: a systematic review. HPB (Oxford) 16:691–698.

24. Oberkofer CE, Hamming JF, Staiger RD, Brosi P, Biondo S, Farges O et al. (2019) Procedural surgical RCTs in daily practice: do surgeons adopt or is it just a waste of time? Ann Surg 270:727–734.

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.hpb.2021.09.006.